Unlocking Access to Biotech Investing.
We are a technology-enabled investment platform providing investors easy access to curated, institutional-grade biotech deals.
The BIOCAPX Model
BIOCAPX uses an alternative model to finance the development of drug candidates that would otherwise be funded as part of a broader company equity or debt financing round. We provide investors with an opportunity to participate in this lucrative asset class without structural constraints, active management, and large fee loads.
We focus on investing in single assets and indications being developed by biotech companies as opposed to the companies themselves by setting up “project focused funds” as a vehicle to house assets through the clinical development process.
BIOCAPX uses a well-defined asset-centric model for investment opportunities, Capital invested goes directly to development costs associated with the clinical trial, which provides a lower investment quantum and higher risk mitigation than in the case of conventional buildouts.
BIOCAPX Investment Fund SICAV plc is licensed by the Malta Financial Services Authority as a self-managed Alternative Investment Fund in terms of the Investment Services Act and is available to Professional and Qualifying Investors.